BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hershberger E, Sloan S, Narayan K, Hay CA, Smith P, Engler F, Jeeninga R, Smits S, Trevejo J, Shriver Z, Oldach D. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study. EBioMedicine 2019;40:574-82. [PMID: 30638863 DOI: 10.1016/j.ebiom.2018.12.051] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Beach SS, Hull MA, Ytreberg FM, Patel JS, Miura TA. Molecular Modeling Predicts Novel Antibody Escape Mutations in the Respiratory Syncytial Virus Fusion Glycoprotein. J Virol 2022;:e0035322. [PMID: 35678603 DOI: 10.1128/jvi.00353-22] [Reference Citation Analysis]
2 Murin CD, Gilchuk P, Crowe JE Jr, Ward AB. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development. Front Immunol 2021;12:808047. [PMID: 35082794 DOI: 10.3389/fimmu.2021.808047] [Reference Citation Analysis]
3 Wu Y, Yin Z, Zhu R, Xu L, Huang Q, Zhang D, Yang H, Zhou Z, Zhang J, Cheng T, Xia N. Development of a rapid neutralization assay for the detection of neutralizing antibodies against coxsackievirus B1. Diagnostic Microbiology and Infectious Disease 2022. [DOI: 10.1016/j.diagmicrobio.2022.115676] [Reference Citation Analysis]
4 Paudyal B, McNee A, Rijal P, Carr BV, Nunez A, McCauley J, Daniels RS, Townsend AR, Hammond JA, Tchilian E. Low Dose Pig Anti-Influenza Virus Monoclonal Antibodies Reduce Lung Pathology but Do Not Prevent Virus Shedding. Front Immunol 2021;12:790918. [PMID: 34975888 DOI: 10.3389/fimmu.2021.790918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lim JJ, Dar S, Venter D, Horcajada JP, Kulkarni P, Nguyen A, Mcbride JM, Deng R, Galanter J, Chu T, Newton EM, Tavel JA, Peck MC. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection. Open Forum Infectious Diseases 2022;9:ofab630. [DOI: 10.1093/ofid/ofab630] [Reference Citation Analysis]
6 Fakhri S, Mohammadi Pour P, Piri S, Farzaei MH, Echeverría J. Modulating Neurological Complications of Emerging Infectious Diseases: Mechanistic Approaches to Candidate Phytochemicals. Front Pharmacol 2021;12:742146. [PMID: 34764869 DOI: 10.3389/fphar.2021.742146] [Reference Citation Analysis]
7 White I, Tamot N, Doddareddy R, Ho J, Jiao Q, Harvilla PB, Yang TY, Geist B, Borrok MJ, Truppo MD, Ganesan R, Chowdhury P, Zwolak A. Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment. MAbs 2021;13:1987180. [PMID: 34693867 DOI: 10.1080/19420862.2021.1987180] [Reference Citation Analysis]
8 Bitterman R, Kumar D. Respiratory Viruses in Solid Organ Transplant Recipients. Viruses 2021;13:2146. [PMID: 34834953 DOI: 10.3390/v13112146] [Reference Citation Analysis]
9 Buchy P, Buisson Y, Cintra O, Dwyer DE, Nissen M, Ortiz de Lejarazu R, Petersen E. COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control. Int J Infect Dis 2021;112:300-17. [PMID: 34563707 DOI: 10.1016/j.ijid.2021.09.045] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
10 Gao F, Zhang X. Pharmacokinetic profiles of a SARS-COV-2 neutralizing antibody BD-604 in cynomolgus monkeys. Drug Test Anal 2021. [PMID: 34215019 DOI: 10.1002/dta.3122] [Reference Citation Analysis]
11 Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 2021;184:3086-108. [PMID: 34087172 DOI: 10.1016/j.cell.2021.05.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
12 Shyr ZA, Cheng YS, Lo DC, Zheng W. Drug combination therapy for emerging viral diseases. Drug Discov Today 2021:S1359-6446(21)00240-3. [PMID: 34023496 DOI: 10.1016/j.drudis.2021.05.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Beigel JH, Hayden FG. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. Cold Spring Harb Perspect Med 2021;11:a038463. [PMID: 32041763 DOI: 10.1101/cshperspect.a038463] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Holzer B, Rijal P, McNee A, Paudyal B, Martini V, Clark B, Manjegowda T, Salguero FJ, Bessell E, Schwartz JC, Moffat K, Pedrera M, Graham SP, Noble A, Bonnet-Di Placido M, La Ragione RM, Mwangi W, Beverley P, McCauley JW, Daniels RS, Hammond JA, Townsend AR, Tchilian E. Protective porcine influenza virus-specific monoclonal antibodies recognize similar haemagglutinin epitopes as humans. PLoS Pathog 2021;17:e1009330. [PMID: 33662023 DOI: 10.1371/journal.ppat.1009330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Mayor A, Chesnay A, Desoubeaux G, Ternant D, Heuzé-Vourc'h N, Sécher T. Therapeutic Antibodies for the Treatment of Respiratory Tract Infections-Current Overview and Perspectives. Vaccines (Basel) 2021;9:151. [PMID: 33668613 DOI: 10.3390/vaccines9020151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 O'Sullivan S, Torres A, Rodriguez A, Martin-Loeches I. Influenza management with new therapies. Curr Opin Pulm Med 2020;26:215-21. [PMID: 32068576 DOI: 10.1097/MCP.0000000000000667] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
17 Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Deliv Rev 2021;169:100-17. [PMID: 33309815 DOI: 10.1016/j.addr.2020.12.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 27.0] [Reference Citation Analysis]
18 Zhang Q, Liang T, Nandakumar KS, Liu S. Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors. Expert Opin Pharmacother 2021;22:715-28. [PMID: 33327812 DOI: 10.1080/14656566.2020.1856814] [Reference Citation Analysis]
19 Salvamani S, Tan HZ, Thang WJ, Ter HC, Wan MS, Gunasekaran B, Rhodes A. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. Br J Biomed Sci 2020;77:168-84. [PMID: 32942955 DOI: 10.1080/09674845.2020.1826136] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
20 Lai SK, McSweeney MD, Pickles RJ. Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19. J Control Release 2021;329:87-95. [PMID: 33276017 DOI: 10.1016/j.jconrel.2020.11.057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Patel H, Kukol A. Integrating molecular modelling methods to advance influenza A virus drug discovery. Drug Discov Today 2021;26:503-10. [PMID: 33220433 DOI: 10.1016/j.drudis.2020.11.014] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Han A, Czajkowski L, Rosas LA, Cervantes-Medina A, Xiao Y, Gouzoulis M, Lumbard K, Hunsberger S, Reed S, Athota R, Baus HA, Lwin A, Sadoff J, Taubenberger JK, Memoli MJ. Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model. Clin Infect Dis 2020:ciaa1725. [PMID: 33211860 DOI: 10.1093/cid/ciaa1725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
23 Pecetta S, Finco O, Seubert A. Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era. Semin Immunol 2020;50:101427. [PMID: 33277154 DOI: 10.1016/j.smim.2020.101427] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
24 Zaraket H, Hurt AC, Clinch B, Barr I, Lee N. Burden of influenza B virus infection and considerations for clinical management. Antiviral Res 2021;185:104970. [PMID: 33159999 DOI: 10.1016/j.antiviral.2020.104970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Heida R, Bhide YC, Gasbarri M, Kocabiyik Ö, Stellacci F, Huckriede ALW, Hinrichs WLJ, Frijlink HW. Advances in the development of entry inhibitors for sialic-acid-targeting viruses. Drug Discov Today 2021;26:122-37. [PMID: 33099021 DOI: 10.1016/j.drudis.2020.10.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Fain B, Dobrovolny HM. Initial Inoculum and the Severity of COVID-19: A Mathematical Modeling Study of the Dose-Response of SARS-CoV-2 Infections. Epidemiologia 2020;1:5-15. [DOI: 10.3390/epidemiologia1010003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
27 Marathe BM, Asthagiri Arunkumar G, Vogel P, Pascua PNQ, Jones J, Webby RJ, Krammer F, Govorkova EA. Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus. Antimicrob Agents Chemother 2020;64:e00284-20. [PMID: 32631823 DOI: 10.1128/AAC.00284-20] [Reference Citation Analysis]
28 Bournazos S, Gupta A, Ravetch JV. The role of IgG Fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020;20:633-643. [PMID: 32782358 DOI: 10.1038/s41577-020-00410-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 145] [Article Influence: 27.0] [Reference Citation Analysis]
29 McNee A, Smith TRF, Holzer B, Clark B, Bessell E, Guibinga G, Brown H, Schultheis K, Fisher P, Ramos S, Nunez A, Bernard M, Graham S, Martini V, Chrun T, Xiao Y, Kash JC, Taubenberger JK, Elliott S, Patel A, Beverley P, Rijal P, Weiner DB, Townsend A, Broderick KE, Tchilian E. Establishment of a Pig Influenza Challenge Model for Evaluation of Monoclonal Antibody Delivery Platforms. J Immunol 2020;205:648-60. [PMID: 32591390 DOI: 10.4049/jimmunol.2000429] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
30 Li Y, Wang L, Si H, Yu Z, Tian S, Xiang R, Deng X, Liang R, Jiang S, Yu F. Influenza virus glycoprotein-reactive human monoclonal antibodies. Microbes Infect 2020;22:263-71. [PMID: 32569735 DOI: 10.1016/j.micinf.2020.06.003] [Reference Citation Analysis]
31 Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, Torres JL, Okba NMA, Claireaux M, Kerster G, Bentlage AEH, van Haaren MM, Guerra D, Burger JA, Schermer EE, Verheul KD, van der Velde N, van der Kooi A, van Schooten J, van Breemen MJ, Bijl TPL, Sliepen K, Aartse A, Derking R, Bontjer I, Kootstra NA, Wiersinga WJ, Vidarsson G, Haagmans BL, Ward AB, de Bree GJ, Sanders RW, van Gils MJ. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 2020;369:643-50. [PMID: 32540902 DOI: 10.1126/science.abc5902] [Cited by in Crossref: 500] [Cited by in F6Publishing: 629] [Article Influence: 250.0] [Reference Citation Analysis]
32 Pawelec G, McElhaney J. Recent advances in influenza vaccines. F1000Res 2020;9:F1000 Faculty Rev-305. [PMID: 32399192 DOI: 10.12688/f1000research.22611.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
33 Martinez MA. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Antimicrob Agents Chemother 2020;64:e00399-20. [PMID: 32152082 DOI: 10.1128/AAC.00399-20] [Cited by in Crossref: 199] [Cited by in F6Publishing: 154] [Article Influence: 99.5] [Reference Citation Analysis]
34 Martinez MA. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Antimicrob Agents Chemother 2020;64:e00399-20. [PMID: 32152082 DOI: 10.1128/AAC.00399-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Sloan SE, Szretter KJ, Sundaresh B, Narayan KM, Smith PF, Skurnik D, Bedard S, Trevejo JM, Oldach D, Shriver Z. Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study. Antiviral Res 2020;184:104763. [PMID: 32151645 DOI: 10.1016/j.antiviral.2020.104763] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Toots M, Plemper RK. Next-generation direct-acting influenza therapeutics. Transl Res 2020;220:33-42. [PMID: 32088166 DOI: 10.1016/j.trsl.2020.01.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
37 Popescu CM, Ursache AL, Feketea G, Bocsan C, Jimbu L, Mesaros O, Edwards M, Wang H, Berceanu I, Neaga A, Zdrenghea M. Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients? Microorganisms 2019;7:E521. [PMID: 31684063 DOI: 10.3390/microorganisms7110521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
38 Dibo M, Battocchio EC, dos Santos Souza LM, da Silva MDV, Banin-hirata BK, Sapla MM, Marinello P, Rocha SP, Faccin-galhardi LC. Antibody Therapy for the Control of Viral Diseases: An Update. CPB 2019;20:1108-21. [DOI: 10.2174/1389201020666190809112704] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
39 Szollosi D, Bill A. Potential Role of Endonuclease Inhibition and Other Targets in the Treatment of Influenza. Curr Drug Targets 2020;21:202-11. [PMID: 31368872 DOI: 10.2174/1389450120666190801115130] [Reference Citation Analysis]
40 Sedeyn K, Saelens X. New antibody-based prevention and treatment options for influenza. Antiviral Res 2019;170:104562. [PMID: 31323236 DOI: 10.1016/j.antiviral.2019.104562] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
41 Principi N, Camilloni B, Alunno A, Polinori I, Argentiero A, Esposito S. Drugs for Influenza Treatment: Is There Significant News? Front Med (Lausanne) 2019;6:109. [PMID: 31192211 DOI: 10.3389/fmed.2019.00109] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
42 Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019;167:45-67. [PMID: 30974127 DOI: 10.1016/j.antiviral.2019.04.006] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 26.3] [Reference Citation Analysis]
43 [DOI: 10.1101/2020.05.12.088716] [Cited by in Crossref: 43] [Cited by in F6Publishing: 11] [Reference Citation Analysis]